Dexcom Inc.
DexCom and Abbott Settle Patent Litigation with Cross-Licensing Agreement
Summary
On December 20, 2024, DexCom, Inc. and Abbott Diabetes Care, Inc. settled their global patent litigation with a cross-licensing agreement. The companies granted each other a worldwide, royalty-free, non-exclusive license to certain patents and patent applications related to analyte sensing. The agreement includes a covenant not to sue until December 20, 2034, and terms to refrain from challenging the licensed patents for varying periods. No financial compensation is required by either party.
Profitelligence Alerts
Get alerts for DXCM
Be first to know when Dexcom Inc. files with the SEC.
Filing Categories
Advertisement
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Official SEC Documents
Advertisement